Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1426 to 1440 of 1515 results for patients and public

  1. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

  2. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

  3. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development Reference number: GID-TA11265 Expected publication date: TBC

  4. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development Reference number: GID-TA11368 Expected publication date: TBC

  5. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

  6. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

  7. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development Reference number: GID-TA11401 Expected publication date: TBC

  8. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

  9. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued Reference number: GID-TA11020

  10. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

  11. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

  12. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development Reference number: GID-TA11044 Expected publication date: TBC

  13. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  14. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026